Key Takeaways
- Volume growth masked by price erosion: CDMO volumes grew ~10% but topline was suppressed by API price declines of 40–50% from COVID peaks, passed through under cost-plus contracts. EBITDA still grew 48.7% YoY in Q4 because unit margins are volume-linked, not topline-linked.
- Jammu plant is the growth catalyst: The greenfield facility is on track for Q2 FY25 commercialization, with a ₹1,000 crore+ revenue target over 3–4 years and a better margin profile driven by GST incentives.
- Sharon acquisition still in gestation: Revenue was flat YoY at ~₹190 crore as the business rebuilds after 4–5 years under IBC; new product and customer efforts have long gestation periods for export markets.
- 20%+ CAGR ambition rests on two bets: Management is confident of 20%+ CDMO CAGR, but this requires both API price stabilization and successful Jammu ramp-up, neither of which is yet proven.
- What to watch next quarter: Jammu commercial production start, any sign of API price floor forming, and whether Sharon’s pipeline begins converting into revenue.
CDMO Business: The Price-Volume Disconnect
- Cost-plus model amplifies price swings: 60–70% of profit margin is fixed (conversion and packing cost), while 40% is variable bill of material. When API prices fall, the topline drops mechanically as savings pass to customers, but unit margins hold steady.
- COVID distortion still unwinding: Paracetamol API peaked at ₹600–₹700/kg during COVID and has since corrected to ~₹300/kg, a 40–50% decline. This topline impact flows through regardless of volume health.
- Volume evidence is in the EBITDA: Q4 EBITDA grew 48.7% YoY and full-year EBITDA grew 35.9% YoY despite flat CDMO sales, confirming underlying volume expansion.
- Pricing decline may be nearing a floor: Management expects no further API price decline next year, citing market speculation that degradation should stop. QoQ decline has moderated to ~2–3%.
- CDMO revenue still below FY22 levels: FY24 CDMO revenue of ₹622 crore compares to ₹687 crore in FY22, with management attributing the gap to price correction and product mix shifts rather than volume loss.
Lohariwala: "if the pricing impact is on the positive side, then the topline growth will be more than like 15%-20% and the price erosion continue, then it can nullify the volume growth. But overall, as you see, our EBITDA is not linked with the topline. EBITDA is linked with the unit margin."
Jammu Facility: The Margin and Growth Thesis
- Four-block greenfield plant on schedule: The facility covers Cephalosporin, Penicillin, Penum and BFS blocks, producing oral solid dosages, dry powder injectables, dry syrup, large and small volume parenterals, and respiratory respules. Commercial production targeted for Q2 FY25.
- Revenue ramp-up timeline: After commercial production begins, revenue should start flowing after 4–5 months, implying a Q3 FY25 contribution. The long-term target is ₹1,000 crore+ from the Jammu block in 3–4 years.
- GST incentive creates margin headroom: The plant benefits from a central scheme for J&K industrial development including 12% GST reimbursement. Management expects to retain some incentive for margin while passing a portion to customers, yielding a better margin profile than existing locations.
- Customer pipeline is advanced: Management reports very good customer feedback and says discussions are in an advanced phase; orders are expected to start flowing once commercial production begins.
Lohariwala: "We are expecting since we may be able to claw back some of the incentive to our margin despite passing some of the portion to our customers. So, we are looking at a better margin profile in Jammu as compared to our existing locations."
Sharon Bio-Medicine: A Slow Rebuild
- Acquired from distress, rebuilding from scratch: Sharon was acquired in June 2023 through the CIRP process after 4–5 years under IBC. It brings CDMO formulation and API capabilities with regulatory access to Canada, UK, Europe, Australia, Korea and Vietnam.
- Revenue flat as pipeline builds: Sharon contributed ~₹190 crore in FY24 versus ~₹192 crore pre-acquisition. Management is working on new products and customers, but export business gestation periods can run into years.
- Tax benefit from accumulated losses: Sharon carries ~₹20–25 crore of accumulated losses that will be set off this year, providing a tax shield. Accounting policies were realigned with Innova group policy this quarter, reducing depreciation.
- Regulated market margins are better: At the consolidated level, Sharon’s regulated business carries better conversion margins, contributing to the gross margin improvement.
Margin and Financial Health
- EBITDA margin jumped 450 bps YoY: Q4 margin improved to 16.7% from 12.2%, driven by product mix shift toward lower-cost products and business mix shift toward higher-margin Univentis Medicare branded generics and Sharon.
- Gross margin benefited from API decline: Lower API prices combined with volume increase expanded gross margins. The consolidated picture includes Sharon’s better regulated-market conversion margins.
- Debt nearly eliminated: Excluding the term loan for the Jammu project, all existing debt has been repaid.
- IPO proceeds deployment on track: ₹62 crore of unutilized IPO proceeds are planned for FY25 deployment, supplemented by ~₹70–75 crore of internal accruals. Other income of ₹6 crore in Q4 came primarily from FD interest on these proceeds.
- Working capital stable: Management aims to maintain the current cash generation cycle range with slight improvements.
- Capacity utilization has headroom: Cephalosporin facility is near optimum at ~70%, but the general facility is at only 40–45% utilization, leaving room for volume growth before Jammu comes online.
Customer and Market Dynamics
- Customer relationships are aging up: A dip in the 5–10 year revenue bucket reflects reclassification as relationships aged into the >10 year bucket, where revenue increased from ₹239 crore to ₹279 crore. Management expects the <5 year cohort to similarly migrate over time.
- Export share stable with slight potential shift: Exports currently represent 23–25% of revenue. If certain business segments grow faster, there could be a 1–2% shift in overall export share.
- Industry CDMO data is opaque: Management stated there is no clear-cut data visibility available from any research agency on industry CDMO growth, making market share comparisons difficult.
- Seasonal pattern is structural: Q1 and Q4 are lower quarters at 22–24% of yearly revenue each, while Q2 and Q3 are higher. The Q3-to-Q4 decline is historically normal.
Lohariwala: "due to this consolidation and free capacity availability, new plant introduction in Jammu with the benefit of GST we are very hopeful and confident to achieve 20%+ CAGR in within this year."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Jammu plant commercialization | All four blocks to commence operations | Q2 FY25 |
| Jammu revenue ramp-up | Revenue to start flowing after commercial production begins | 4–5 months post-start, i.e., Q3 FY25 |
| Jammu long-term revenue target | ₹1,000 crore+ from Jammu block | 3–4 years |
| CDMO volume growth | 10%+ double-digit volume growth | Ongoing |
| CDMO topline growth | 15–20% if pricing is positive; flat if price erosion continues | Conditional on API price direction |
| CDMO CAGR target | 20%+ CAGR in CDMO category | Coming year |
| API price outlook | No further decline expected; base should stabilize | Next year |
| Long-term company CAGR | 20%+ CAGR | Next 3–4 years |
| Sharon accumulated loss set-off | ~₹20–25 crore tax benefit | This year |
| General facility utilization | Improvement from current 40–45% | Forward-looking, undated |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Total income | ₹268.3 cr, +10.2% YoY |
| EBITDA | ₹43.8 cr, +48.7% YoY |
| EBITDA margin | 16.7%, vs 12.2% in Q4 FY23 |
| Profit after tax | ₹28.7 cr, +66.5% YoY |
| Total income (FY24 full year) | ₹1,093.8 cr, +16.9% YoY |
| EBITDA (FY24 full year) | ₹166.9 cr, +35.9% YoY |
| PAT (FY24 full year) | ₹94.3 cr, +38.9% YoY |
| CDMO revenue contribution | 53% of total income for the quarter |
| Domestic branded generics contribution | 18% of total income for the quarter |
| International branded generics contribution | 11% of total income for the quarter |
| Sharon Bio-Medicine contribution | 18% of total income for the quarter |
| CDMO volume growth (FY24) | ~10%, offset by API price decline |
| CDMO customer count | 193 as of FY24 |
| Cephalosporin facility utilization | ~70% |
| General facility utilization | 40%–45% |
| Sharon Bio-Medicine EBITDA margin | ~26%–27% for Q4 FY24 |
| Jammu plant gross block | ~₹460 cr, commercialization expected Q2 FY25 |
| Jammu plant expected annual GST benefit | ~₹85–₹90 cr |
| Net cash from operating activities (FY24) | ₹70–₹75 cr deployed in fixed deposits from internal accruals |